Fig. 2: Investigator-assessed PFS estimated using Kaplan–Meier methodology. | Nature Communications

Fig. 2: Investigator-assessed PFS estimated using Kaplan–Meier methodology.

From: Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial

Fig. 2: Investigator-assessed PFS estimated using Kaplan–Meier methodology.

A Intention-to-treat population (two-sided log-rank test stratified on predefined stratification factors). B p53-abnormal subgroup. C LGEhigh subgroup. D Subgroup with complete response to prior chemotherapy. CI confidence interval, LGE large genomic events, PFS progression-free survival. Vertical bars, censoring.

Back to article page